133 related articles for article (PubMed ID: 3583385)
1. Carcinogenicity of cytostatic triazenes.
Kolar GF
IARC Sci Publ; 1986; (78):111-26. PubMed ID: 3583385
[TBL] [Abstract][Full Text] [Related]
2. Carcinogenicity of the antineoplastic agent, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, and its metabolites in rats.
Beal DD; Skibba JL; Croft WA; Cohen SM; Bryan GT
J Natl Cancer Inst; 1975 Apr; 54(4):951-7. PubMed ID: 1127724
[TBL] [Abstract][Full Text] [Related]
3. Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide and its metabolites on Novikoff hepatoma cells.
Beal DD; Skibba JL; Whitnable KK; Bryan GT
Cancer Res; 1976 Aug; 36(8):2827-31. PubMed ID: 179708
[TBL] [Abstract][Full Text] [Related]
4. Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma.
Sava G; Giraldi T; Lassiani L; Nisi C
Cancer Res; 1984 Jan; 44(1):64-8. PubMed ID: 6690062
[TBL] [Abstract][Full Text] [Related]
5. 5-(3-Hydroxymethyl-3-methyl-1-triazeno imidazole-4-carboxamide is a metabolite of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DIC, DTIC NSC-45388).
Kolar GF; Maurer M; Wildschütte M
Cancer Lett; 1980 Sep; 10(3):235-41. PubMed ID: 7427920
[TBL] [Abstract][Full Text] [Related]
6. [DTIC in the therapy of solid tumours (author's transl)].
Kokron O; Pridun N; Zischinsky W
Wien Klin Wochenschr; 1978 Dec; 90(24):864-7. PubMed ID: 741753
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of triazenoazaindoles: a new class of triazenes with antitumor activity.
Diana P; Stagno A; Barraja P; Carbone A; Parrino B; Dall'Acqua F; Vedaldi D; Salvador A; Brun P; Castagliuolo I; Issinger OG; Cirrincione G
ChemMedChem; 2011 Jul; 6(7):1291-9. PubMed ID: 21523910
[TBL] [Abstract][Full Text] [Related]
8. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1.
Reid JM; Kuffel MJ; Miller JK; Rios R; Ames MM
Clin Cancer Res; 1999 Aug; 5(8):2192-7. PubMed ID: 10473105
[TBL] [Abstract][Full Text] [Related]
9. Experimental studies at Southern Research Institute with DTIC (NSC-45388).
Montgomery JA
Cancer Treat Rep; 1976 Feb; 60(2):125-34. PubMed ID: 1260770
[TBL] [Abstract][Full Text] [Related]
10. Properties of human melanoma cells resistant to 5-(3',3'-dimethyl-1-triazeno)imidazole-4-carboxamide and other methylating agents.
Parsons PG; Smellie SG; Morrison LE; Hayward IP
Cancer Res; 1982 Apr; 42(4):1454-61. PubMed ID: 7060019
[No Abstract] [Full Text] [Related]
11. [Dimethyl-triazeno-imidazol-carboxamide (DTIC)--a new cytostatic agent].
Klepp O
Tidsskr Nor Laegeforen; 1975 Sep; 95(27):1550-1. PubMed ID: 1179374
[No Abstract] [Full Text] [Related]
12. Urogenital anomalies in fetal rats produced by the anticancer agent 4(5)-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide.
Chaube S; Swinyard CA
Anat Rec; 1976 Nov; 186(3):461-9. PubMed ID: 999039
[TBL] [Abstract][Full Text] [Related]
13. Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide.
Safgren SL; Reid JM; Rios R; Ames MM
J Chromatogr B Biomed Sci Appl; 2001 Apr; 754(1):91-6. PubMed ID: 11318431
[TBL] [Abstract][Full Text] [Related]
14. Microsomal metabolism of triazenylimidazoles.
Hill DL
Cancer Res; 1975 Nov; 35(11 Pt 1):3106-10. PubMed ID: 241485
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
Tsang LL; Quarterman CP; Gescher A; Slack JA
Cancer Chemother Pharmacol; 1991; 27(5):342-6. PubMed ID: 1998993
[TBL] [Abstract][Full Text] [Related]
16. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic effects of the methylating agent 5-(3-methyl-1-triazeno) imidazole-4-carboxamide in human melanoma cells.
Hayward IP; Parsons PG
Aust J Exp Biol Med Sci; 1984 Oct; 62 ( Pt 5)():597-606. PubMed ID: 6534346
[TBL] [Abstract][Full Text] [Related]
18. Effects of dimethyltriazenes on in vitro Lewis lung carcinoma tumor lines with different metastatic capacity.
Zupi G; Corsi A; Sacchi A; Lassiani L; Giraldi T
Invasion Metastasis; 1984; 4(3):179-88. PubMed ID: 6480290
[TBL] [Abstract][Full Text] [Related]
19. Modulating effect of new potential antimelanomic agents, spin-labeled triazenes and nitrosoureas on the DOPA-oxidase activity of tyrosinase.
Gadjeva V; Zheleva A; Raikova E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):99-108. PubMed ID: 10738906
[TBL] [Abstract][Full Text] [Related]
20. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
